Compare Cassava Sciences Inc (FLNA) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs MasTec Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while MasTec Inc trades at $219.65 (market cap $17.94B). The key difference: MasTec Inc is far larger — about 455.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 1,292,386). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and MasTec Inc for 23 Days on average.
| FLNA | MTZ | |
|---|---|---|
Market Cap | $39.40M | $17.94B |
Volume | 759,018 | 1,292,386 |
Sector | Health | Industrials |
52-Week High | $4.64 | $437.51 |
52-Week Low | $0.68 | $190.08 |
Typical Hold Time | 37 Days | 23 Days |
Enterprise Value | -$43.28M | $20.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
MasTec (MTZ) trades at $223.37, down 2.16% today, with technical indicators showing a neutral bias amid mixed moving average signals. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 88.9% buy ratings and a $408.58 consensus price target representing significant upside potential from current levels.
MTZ's infrastructure expertise positions it well for AI-driven data center and utility investment cycles, though premium valuation metrics and recent cash flow volatility present near-term risks. The stock's investment case hinges on execution of record backlog and margin expansion amid competitive infrastructure markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
